Share on StockTwits

Tornier N.V. (NASDAQ:TRNX) issued its quarterly earnings data on Thursday. The company reported ($0.22) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.15) by $0.07, Analyst Ratings News reports. The company had revenue of $83.40 million for the quarter, compared to the consensus estimate of $76.21 million.

On the ratings front, analysts at Barclays raised their price target on shares of Tornier N.V. from $20.00 to $23.00 in a research note on Thursday, January 9th. They now have an “overweight” rating on the stock. One analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $19.29.

Shares of Tornier N.V. (NASDAQ:TRNX) traded up 0.26% on Thursday, hitting $19.33. 392,661 shares of the company’s stock traded hands. Tornier N.V. has a 52 week low of $15.17 and a 52 week high of $21.87. The stock’s 50-day moving average is $19.0 and its 200-day moving average is $19.00. The company’s market cap is $937.1 million. Tornier N.V. also was the target of a significant decline in short interest during the month of January. As of January 31st, there was short interest totalling 879,587 shares, a decline of 29.1% from the January 15th total of 1,241,233 shares. Approximately 3.0% of the company’s stock are sold short. Based on an average daily trading volume, of 224,105 shares, the short-interest ratio is presently 3.9 days.

Tornier N.V. (NASDAQ:TRNX) is a global medical device company focused on surgeons that treat musculoskeletal injuries and disorders of the shoulder, elbow, wrist, hand, ankle and foot.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.